Compound hub
PT-141
PT-141 is the research name for bremelanotide, a lab-made, ring-shaped peptide of seven amino acids. Bremelanotide switches on several melanocortin receptors, docking sites found on skin and nerve cells. The US FDA approved one prescription product containing it in 2019, for a narrow group of adult women. This hub answers the questions people ask about PT-141 from the FDA label, trial registry records and published papers. It also says plainly where the evidence stops.
Record card
| Common name | PT-141 |
|---|---|
| Generic name | Bremelanotide |
| Structure | Cyclic heptapeptide (7 amino acids), Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH) (FDA label, 2019) |
| Formula and weight | C50H68N14O10; molecular weight 1025.2, free base (FDA label, 2019) |
| CAS (database identifier) | 189691-06-3 (PubChem) |
| Class | Melanocortin receptor agonist; analogue of alpha-melanocyte-stimulating hormone |
| Approved product | Vyleesi, FDA approval in 2019 (FDA label, 2019), for premenopausal women with acquired, generalised hypoactive sexual desire disorder |
| Pivotal trials | NCT02333071 and NCT02338960, phase 3, 24 weeks, placebo-controlled |
| Terminal half-life, single administration | About 2.7 hours, range 1.9 to 4.0 (FDA label, 2019) |
| Poisons Standard, October 2026 (F2026L01327) | No individual bremelanotide or PT-141 entry in the instrument text, searched 16 October 2026 |
| WADA 2026 Prohibited List | Bremelanotide not named in the List text, searched 16 October 2026 |
Questions answered here
05- How does PT-141 work? Melanocortin receptors and what the label saysHow PT-141 (bremelanotide) works at the receptor level: which melanocortin receptors it activates, what the FDA label says about its unknown mechanism for desire, and how the body handles the peptide.Updated 2026-10-16
- Is PT-141 legal in Australia? Poisons Standard, TGA, FDA and WADA recordsWhat the October 2026 Poisons Standard, the TGA, the FDA and the WADA 2026 Prohibited List say about PT-141 (bremelanotide), with the date each record was checked. Records only; this is not legal advice.Updated 2026-10-16
- PT-141 side effects: nausea, flushing, blood pressure and skin darkening in the FDA labelWhat the FDA label and the phase 3 trials record about PT-141 (bremelanotide) side effects: how often nausea, flushing and headache occurred, the blood pressure and heart rate changes, focal hyperpigmentation, and what the records do not cover.Updated 2026-10-16
- PT-141 study findings: what the phase 3 trials measured and foundWhat the two phase 3 RECONNECT trials of PT-141 (bremelanotide) measured, what the questionnaire scores showed against placebo, who took part, who left early, and which registered studies exist.Updated 2026-10-16
- What is PT-141? Bremelanotide explained from the label and the trialsWhat PT-141 is: the research name for bremelanotide, a ring-shaped peptide of seven amino acids that acts on melanocortin receptors, what the FDA approved in 2019, and what the approval does and does not cover.Updated 2026-10-16
Form Laboratories supplies research-use-only reference material. Everything in this hub is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.